By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Keryx Biopharmaceuticals 

750 Lexington Avenue, 26th Floor

New York  New York  10022  U.S.A.
Phone: 212-531-5965 Fax: 212-531-5961


SEARCH JOBS


Industry
Biotechnology






Company News
Keryx (KERX) Announces Second Quarter 2017 Financial Results And Increased 2017 U.S. Product Sales Guidance 7/27/2017 10:42:47 AM
Keryx (KERX) Announces First Quarter 2017 Financial Results 5/4/2017 11:13:28 AM
Keryx (KERX) Announces That Auryxia (Ferric Citrate) Is Now On Formulary At All Major Medicare Part D Plans 5/1/2017 10:51:27 AM
Keryx (KERX) To Host Conference Call Of First Quarter 2017 Financial Results On Thursday, May 4, 2017 4/18/2017 8:38:52 AM
Keryx (KERX) Announces The Largest Medicare Part D Plan Sponsor Added Auryxia To Its Medicare Part D Plan Formularies 3/20/2017 9:00:52 AM
Keryx (KERX) Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Auryxia (Ferric Citrate) Tablets 3/8/2017 10:15:17 AM
Keryx (KERX) Announces Fourth Quarter And Full Year 2016 Financial Results 3/1/2017 11:24:07 AM
Keryx (KERX) To Host Conference Call Of Fourth Quarter And Full Year 2016 Financial Results On Wednesday, March 1, 2017 2/16/2017 8:03:56 AM
Keryx (KERX) Release: Biopharma Announces Publication Of Auryxia (Ferric Citrate) Phase III Trial Results For Iron Deficiency Anemia (IDA) In Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) In Journal Of The American Society Of Nephrology 12/8/2016 3:06:46 PM
Keryx (KERX) Announces Case Study Data Of Auryxia Presented At American Society of Nephrology’s Kidney Week 11/21/2016 10:47:26 AM
12345678910...
//-->